论文部分内容阅读
目的评价125I放射性粒子植入联合GP方案治疗老年非小细胞肺癌(NSCLC)的可行性、安全性及其疗效。方法40例NSCLC中,初治24例,复治16例。男32例,女8例。年龄60~75岁。均行CT引导下瘤体内125I粒子植入后3~5天,予GP方案:GEM 1 000 mg/m2,静滴30 m in,第1、8、15天;DDP 30 mg/m2,静滴,第1~3天,28 d为一周期,化疗2~4个周期。粒子植入后2个月(即化疗2周期后)进行近期疗效及毒副反应评价。结果125I放射性粒子植入2个月后,40例患者全部可评价疗效。全组CR 9例,PR 23例,SD 5例,PD 3例,总有效率80.0%。初治组24例中,CR 6例,PR 14例,SD 3例,PD 1例,有效率83.3%;复治组16例中,CR 3例,PR 9例,SD 2例,PD 2例,有效率75.0%,两组差异无显著性(P>0.05)。结论125I放射性粒子植入联合GP方案化疗对不能手术的老年NSCLC患者是一种安全、可行、有效的治疗方法。
Objective To evaluate the feasibility, safety and efficacy of 125I radioactive particle implantation combined with GP regimen in the treatment of elderly non-small cell lung cancer (NSCLC). Methods 40 cases of NSCLC, initial treatment in 24 cases, retreatment in 16 cases. 32 males and 8 females. Age 60 to 75 years old. Under the guidance of CT, 3 to 5 days after 125I implantation in the tumor, the GP regimen: GEM 1 000 mg / m2, intravenous infusion for 30 min, days 1, 8 and 15; DDP 30 mg / m2, , 1 to 3 days, 28 days for a cycle, chemotherapy 2 to 4 cycles. Two months after the implantation of particles (ie 2 cycles of chemotherapy) for short-term efficacy and toxicity evaluation. Results After 125I radioactive seeds were implanted for 2 months, all 40 patients could evaluate the curative effect. The whole group CR 9 cases, PR 23 cases, SD 5 cases, PD 3 cases, the total efficiency of 80.0%. The initial treatment group of 24 cases, CR 6 cases, PR 14 cases, SD 3 cases, PD 1 cases, the effective rate was 83.3%; retreatment group of 16 cases, CR 3 cases, PR 2 cases, SD 2 cases, PD 2 cases , The effective rate was 75.0%, no significant difference between the two groups (P> 0.05). Conclusion The 125I radioactive seed implantation combined with GP regimen is a safe, feasible and effective treatment for elderly inoperable NSCLC patients.